Physician profile
Kashif Ali
NPI 1851423388
$987,233.59
in general payments reported to CMS, 2019-2025
100 companies · $145K in 2025
The $145K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $24K · 2021: $133K · 2022: $198K · 2023: $168K · 2024: $222K · 2025: $145K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $377K · Consulting Fee: $88K · Travel and Lodging: $44K · Food and Beverage: $21K · Long Term Medical Supply Or Device Loan: $1,799 · Honoraria: $1,625 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,350 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $377,082.35 |
| Consulting Fee | $88,167.65 |
| Travel and Lodging | $44,152.63 |
| Food and Beverage | $20,504.74 |
| Long Term Medical Supply Or Device Loan | $1,799.04 |
| Honoraria | $1,625.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,350.00 |
| Education | $350.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $331,005.96 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $189,867.68 | 2019-2025 | Calquence, Tagrisso, Imfinzi |
| Genzyme Corporation | $182,514.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $87,850.05 | 2019-2025 | Libtayo |
| Sobi, INC | $50,226.27 | 2022-2025 | |
| Celgene Corporation | $15,238.46 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $14,545.18 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $14,188.37 | 2019-2025 | Venclexta |
| Exelixis INC. | $9,252.30 | 2019-2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $9,145.67 | 2020-2025 | Clonoseq |
| Janssen Biotech, INC. | $6,216.01 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $5,694.88 | 2019-2023 | Tivdak, Adcetris |
| Beigene USA, INC. | $5,006.51 | 2022-2024 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $4,967.41 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Novartis Pharmaceuticals Corporation | $4,822.03 | 2019-2025 |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $4,539.62 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $4,348.79 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Eisai INC. | $4,311.33 | 2019-2025 | |
| Global Blood Therapeutics, INC. | $4,272.63 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,220.69 | 2019-2025 | |
| Syndax Pharmaceuticals, INC. | $3,437.04 | 2025 | Revuforj |
| Stemline Therapeutics INC. | $3,407.60 | 2021-2025 | Orserdu |
| Pfizer INC. | $3,207.34 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $2,575.64 | 2021-2024 | Stimufend |
| Tesaro, INC. | $2,509.09 | 2019 | |
| Emd Serono, INC. | $1,720.64 | 2019-2025 | |
| Taiho Oncology, INC. | $1,611.44 | 2019-2025 | |
| Heron Therapeutics, INC. | $1,517.71 | 2019-2023 | Sustol |
| Cti Biopharma Corp. | $1,471.55 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $1,447.35 | 2020-2025 | Jemperli, Zejula |
| Genentech USA, INC. | $1,273.79 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $1,210.28 | 2020-2025 | |
| Amgen INC. | $678.00 | 2019-2025 | Lumakras, Blincyto, Kyprolis |
| Daiichi Sankyo INC. | $659.19 | 2019-2025 | Injectafer, Enhertu, Vanflyta |
| Beigene, LTD. | $525.00 | 2021 | |
| Lilly USA, LLC | $515.19 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $483.83 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Astellas Pharma US INC | $383.82 | 2019-2025 | Padcev, Cresemba, Vyloy |
| Legend Biotech USA INC. | $346.72 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $313.70 | 2019-2025 | Xarelto, Erleada |
| Aveo Pharmaceuticals, INC. | $290.79 | 2022-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $284.06 | 2020-2025 | Xpovio |
| Dendreon Pharmaceuticals LLC | $270.67 | 2019-2025 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $270.07 | 2019-2023 | Imbruvica |
| Cardinal Health 110 LLC | $250.00 | 2024 | |
| Pharmaessentia USA Corporation | $244.29 | 2022-2025 | Besremi |
| Tersera Therapeutics LLC | $242.18 | 2019-2025 | Xermelo |
| Ipsen Biopharmaceuticals, INC | $207.30 | 2019-2025 | Tazverik, Onivyde |
| Puma Biotechnology, INC. | $184.08 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $179.05 | 2019-2024 | Ultomiris |
| Asd Specialty Healthcare, LLC | $163.10 | 2019 | |
| Caris Mpi, INC. | $161.53 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $152.84 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $144.06 | 2020-2025 | Monoferric |
| Kite Pharma, INC. | $137.02 | 2019-2023 | Yescarta |
| Myriad Genetic Laboratories, INC. | $134.70 | 2020-2023 | Precisetumor |
| Secura Bio, INC. | $129.85 | 2020-2021 | |
| Clovis Oncology, INC. | $122.95 | 2019-2021 | |
| Dexcom, INC. | $119.51 | 2023 | Dexcom G6 Transmitter |
| Genmab U.S., INC. | $111.58 | 2023-2024 | Epkinly |
| Kyowa Kirin, INC. | $110.52 | 2021-2025 | Poteligeo |
| Tempus Ai, INC | $103.02 | 2025 | Xt Cdx |
| Sanofi-Aventis U.S. LLC | $100.01 | 2019-2022 | |
| Beone Medicines USA, INC. | $97.24 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $91.26 | 2022-2025 | |
| Morphosys, US INC. | $89.62 | 2021-2023 | Monjuvi |
| Sumitomo Pharma America, INC. | $85.90 | 2023-2025 | Orgovyx |
| G1 Therapeutics, INC. | $84.88 | 2022-2023 | Cosela |
| Eusa Pharma (US) LLC | $78.13 | 2020-2022 | |
| Acrotech Biopharma INC. | $73.10 | 2021-2025 | Beleodaq |
| Blueprint Medicines Corporation | $71.95 | 2021-2025 | Ayvakit |
| Recordati_rare_diseases_inc. | $69.57 | 2023-2025 | Sylvant |
| Gilead Sciences, INC. | $69.46 | 2021-2025 | Trodelvy |
| Boston Scientific Corporation | $59.71 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Tactile Systems Technology INC | $59.57 | 2021-2022 | |
| Accord Healthcare, INC. | $45.51 | 2024 | |
| Spectrum Pharmaceuticals INC. | $45.03 | 2023-2024 | Rolvedon |
| Tolmar Pharmaceuticals, INC. | $37.96 | 2021-2022 | |
| Lundbeck LLC | $32.54 | 2022 | |
| Servier Pharmaceuticals LLC | $30.36 | 2024-2025 | |
| Foundation Medicine, INC. | $29.54 | 2019-2020 | |
| Shield Therapeutics INC | $27.94 | 2025 | |
| Amag Pharmaceuticals, INC. | $27.68 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $27.67 | 2022-2025 | Qinlock, Tgct |
| Iovance Biotherapeutics, INC. | $27.17 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $26.94 | 2019 | |
| Tg Therapeutics, INC. | $24.90 | 2021 | |
| Invivyd INC | $23.64 | 2024 | Pemgarda |
| Telix Pharmaceuticals | $23.35 | 2023 | Illuccix |
| Immunogen, INC. | $22.95 | 2023 | Elahere |
| Dova Pharmaceuticals | $22.80 | 2021 | |
| Mylan Institutional INC. | $22.62 | 2019 | |
| Epizyme, INC. | $22.27 | 2021 | |
| Geron Corporation | $20.87 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $20.78 | 2025 | Ogsiveo |
| Sun Pharmaceutical Industries INC. | $18.97 | 2020 | |
| Acceleron Pharma, INC. | $18.51 | 2020 | |
| Aurobindo Pharma USA, INC. | $16.59 | 2020 | |
| Shire North American Group INC | $15.70 | 2019 | |
| Janssen Scientific Affairs, LLC | $15.10 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.